Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

First Posted Date
2014-07-03
Last Posted Date
2020-04-21
Lead Sponsor
Xijing Hospital
Target Recruit Count
239
Registration Number
NCT02181361
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-06-23
Last Posted Date
2015-12-22
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
20
Registration Number
NCT02169440
Locations
🇵🇹

BIAL - Portela & Cª - Human Pharmacology Unit (UFH), S. Mamede do Coronado, Trofa, Portugal

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

First Posted Date
2014-06-12
Last Posted Date
2019-11-07
Lead Sponsor
University Hospital, Angers
Target Recruit Count
51
Registration Number
NCT02161965
Locations
🇫🇷

University Hospital Angers, Angers, France

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-06-12
Last Posted Date
2018-10-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
24
Registration Number
NCT02161731
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-03-18
Last Posted Date
2019-04-23
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
66
Registration Number
NCT02090075
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Torrance, California, United States

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

First Posted Date
2014-02-26
Last Posted Date
2019-03-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
2199
Registration Number
NCT02072434
Locations
🇪🇸

First site in, Madrid, Spain

🇪🇸

Third site in, Madrid, Spain

🇩🇪

Bad Friedrichshall, Heilbronn, Germany

and more 1 locations

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

First Posted Date
2014-02-25
Last Posted Date
2020-02-17
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
52
Registration Number
NCT02070510
Locations
🇩🇪

Novo Nordisk Investigational Site, Berlin, Germany

Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity

First Posted Date
2014-02-21
Last Posted Date
2017-04-27
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
376
Registration Number
NCT02069132
Locations
🇮🇹

Second University of Naples, Napoli, Italy

🇮🇹

University of Naples Federico II, Napoli, Italy

🇮🇹

University of Salerno, Salerno, Italy

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

First Posted Date
2014-01-23
Last Posted Date
2017-02-08
Lead Sponsor
Asan Medical Center
Target Recruit Count
195
Registration Number
NCT02042534
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath